520 related articles for article (PubMed ID: 32705213)
1. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
2. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
4. Integrated bioinformatics analysis for differentially expressed genes and signaling pathways identification in gastric cancer.
Yang C; Gong A
Int J Med Sci; 2021; 18(3):792-800. PubMed ID: 33437215
[No Abstract] [Full Text] [Related]
5. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
6. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
7. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
8. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
9. Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
Gui T; Yao C; Jia B; Shen K
PLoS One; 2021; 16(6):e0253136. PubMed ID: 34143800
[TBL] [Abstract][Full Text] [Related]
10. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract][Full Text] [Related]
11. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments.
Zhang T; Guo J; Gu J; Wang Z; Wang G; Li H; Wang J
Oncol Rep; 2019 Jan; 41(1):279-291. PubMed ID: 30542696
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
13. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
14. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
[TBL] [Abstract][Full Text] [Related]
15. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
17. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
18. An Integrated Microarray Analysis Reveals Significant Diagnostic and Prognostic Biomarkers in Pancreatic Cancer.
Yang ZQ; Liu YJ; Zhou XL
Med Sci Monit; 2020 Apr; 26():e921769. PubMed ID: 32235821
[TBL] [Abstract][Full Text] [Related]
19. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
Zhang L; Sun L; Zhang B; Chen L
Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy.
Sad LMAE; Mohamed DA; Elanwar NM; Elkady A
J Cancer Res Ther; 2021; 17(6):1454-1461. PubMed ID: 34916377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]